INS and atrial fibrillation: As shown in Tables 4 and 5, participants who required a loop diuretic dose escalation (increase) were more frequently assigned to the placebo group and were more likely to have the following at baseline: NYHA class III/IV symptoms, atrial fibrillation, obstructive sleep apnoea, and treatment with insulin.